Oligometastatic Cancer

Safely deliver ablative doses, with up to 100% reduction in grade 3+ toxicity

Delivering SBRT and hypofractionated radiation therapy using conventional technology has been shown to increase toxicity.1,2 However, studies show MRIdian SBRT significantly decreases toxicity.1,2 Patients may see up to 100% reduction in grade 3+ toxicity when treating oligomets.1,2

These outcomes are accomplished by:

  • Delivering treatment with real-time MRI imaging
  • Providing daily on-table adaption to account for any changes in the position of the tumor and nearby organs-at-risk
  • Tracking the tumor in real-time, so clinicians can see the tumor throughout the treatment
  • Using real-time beam gating to protect surrounding healthy tissue and deliver an optimal dose to the tumor; when the tumor moves out of the target area, the beam automatically stops

Scroll down to learn more about MRIdian treatment for oligometastatic cancer.

1Palma DA, Olson R, Harrow S, et al. (2019). Stereotactic ablative radiotherapy versus standard of care palliative treatment in patients with oligometastatic cancers (SABR-COMET): a randomised, phase 2, open-label trial. Lancet, 393(10185):2051–2058.
2Henke, L., et al. (2018). Phase I trial of stereotactic MR-guided online adaptive radiation therapy (SMART) for the treatment of oligometastatic or unresectable primary malignancies of the abdomen. Radiotherapy and Oncology, 126(3), 519–526.

Important Safety Information

Indications for Use (IFU): The MRIdian Linac system, with magnetic resonance imaging capabilities, is intended to provide stereotactic radiosurgery and precision radiotherapy for lesions, tumors, and conditions anywhere in the body where radiation treatment is indicated. The MRIdian Linac System is not appropriate for all patients, including those who are not candidates for magnetic resonance imaging.

Important Safety Information (ISI): Radiation treatments may cause side effects that can vary depending on the part of the body being treated. The most frequent ones are typically temporary and may include, but are not limited to, irritation to the respiratory, digestive, urinary or reproductive systems; fatigue; nausea; skin irritation; and hair loss. In some patients, side effects can be severe. Treatment sessions may vary in complexity and duration.

Radiation treatment is not appropriate for all cancers. You should discuss the potential for side effects and their severity as well as the benefits of radiation and magnetic resonance imaging with your doctor to make sure radiation treatment is right for you.

Disclaimer: The opinions and clinical experiences presented herein are specific to the featured physicians and the featured patients and are for information purposes only. Nothing in this material is intended to provide specific medical advice or to take the place of written law or regulations. Results of treatment presented in the videos and information on this webpage are not indicative of typical or future results.

Discuss treatment options with your doctor, including the risks and benefits of the entire course of treatment specific to your individual needs. MRIdian Linac systems are only available at appropriately equipped facilities with specially trained physicians.

Only On MRIdian

James Good, MD, Clinical Director of SBRT, GenesisCare Oxford

Patient: 54-yo female; ER(+) HER2(-) primary breast tumor, previously Tx w/ lumpectomy and post-op RT; presented with 3 liver mets on FDG PET and MRI

Treatment Options: Surgery too risky, not able to get complete disease; standard radiation not an option

Challenge: Lesion location: Very susceptible to motion; requires complex setup w/ abdominal compression and fiducials; movement up to 2 cm would lead to large ITV and irradiating healthy tissue; conventional Linac would compromise PTV dose to meet OAR constraints; likely reduce overall dose to avoid exceeding mean liver tolerance

MRIdian: 35 Gy in 5 Fx, keeping OARs in tolerance; daily adaptation for ablative dose to tumor while keeping critical structures within tolerance; real-time automated beam gating with patient directed breath-hold allowed accurate dose delivery

Outcome: Able to deliver 50 Gy to three lesions. Three-month follow-up shows clear ablation zone and elimination of tumor

Case courtesy of Dr. Good –  GenesisCare Oxford. Results of this case study are not predictive of future results. The opinions and clinical experiences presented herein are specific to the featured physicians and the featured patients and are for informational purposes only. Nothing in this material is intended to provide specific medical advice or to take the place of written law or regulations.

Only On MRIdian

“One and done”: Treating Multiple Oligetastatic Lesions 

Michael Chuong, MD, Director, MR-Guided Radiation Therapy and Proton Therapy, Miami Cancer Institute

Patient: 65-yo male diagnosed with Stage-1 NSCLC

Treatment Options: Surgery vs. standard 5 fx SBRT (patient declined surgery)

Challenge: Infection risk to compromised cancer patient; similar patient would be treated in 5 Fx, increasing number of healthcare encounters (and risk of exposure to COVID-19 in these times)

MRIdian: Confidence to deliver 34 Gy in 1 Fx; breath-hold delivery with visual feedback to maintain chest wall dose constraints; 3 mm PTV margins, automated beam gating for intrafraction motion; total treatment time 40 min door-to-door

Outcome: Patient doing well, no acute toxicities reported, opportunity to treat multiple oligomets in different location efficiently with single fraction option

Case courtesy of Dr. Choung, Miami Cancer Institute. Results of this case study are not predictive of future results. The opinions and clinical experiences presented herein are specific to the featured physicians and the featured patients and are for informational purposes only. Nothing in this material is intended to provide specific medical advice or to take the place of written law or regulations

Key Study Summary

Physician Spotlight + Key Charts and Data

Webinars and Videos

  Global Info

CUSTOMER LOGIN

Please log in to access the ViewRay Customer Portal. To request access, please click here. Request will be reviewed within 2 business days.

Existing Users Log In
   

This site uses cookies and other tracking technologies to assist with navigation and your ability to provide feedback, analyze your use of our products and services, assist with our promotional and marketing efforts, and provide content from third parties. Cookie Policy

Accept